CHMP News & Analysis
2 articles
Market Mood
Omeros (OMER) Faces CHMP Review, Price Target Cut to $33
Omeros Corp. (NASDAQ: OMER) received a negative opinion from the Committee for Medicinal Products for Human Use (CHMP) regarding its marketing authorization for narsoplimab, an antibody targeting MASP-2 for treating hematopoietic stem cell transplant-related thrombotic microangiopathy. Following this, analyst Brandon Folkes from H.C. Wainwright reduced the price target from $40 to $33, suggesting an upside of more than 233%. Despite the setback, Folkes maintained a Buy rating, emphasizing the U.S. launch as a potential key value driver for the stock. This matters for investors as it highlights both risks and potential rewards in Omeros’ future growth strategies.
Read More: Omeros (OMER) Faces CHMP Review, Price Target Cut to $33
Rhythm Pharmaceuticals Stock Rating Reiterated by Leerink Following CHMP Opinion
Leerink Partners has reiterated its stock rating for Rhythm Pharmaceuticals following a positive opinion from the Committee for Medicinal Products for Human Use (CHMP). This reiteration suggests confidence in Rhythm's ongoing developments in the treatment of rare diseases. As a result, the stock’s stability and potential for growth in the market may increase, depending on investor reaction to the reaffirmed rating and forthcoming product developments. No specific price or P/E ratios were mentioned in the article.
Read More: Rhythm Pharmaceuticals Stock Rating Reiterated by Leerink Following CHMP Opinion